©The Author(s) 2019. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Otorhinolaryngol. Apr 27, 2019; 8(1): 1-3
Published online Apr 27, 2019. doi: 10.5319/wjo.v8.i1.1
CX3CR1 receptor as a potential therapeutic target in chronic rhinosinusitis and allergic rhinitis
Amr El-Shazly, Department of Otolaryngology, Liège University Hospital, Liège 4000, Belgium
Author contributions: El-Shazly A contributed to the manuscript.
Conflict-of-interest statement: No potential conflicts of interest relevant to this article were reported.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Corresponding author: Amr El-Shazly, MD, PhD, Professor, Department of Otolaryngology, Liège University Hospital, Laboratory of Experimental Pathology-Experimental Rhinology Unit, Liège 4000, Belgium. email@example.com
Received: June 15, 2018
Peer-review started: June 15, 2018
First decision: August 9, 2018
Revised: January 23, 2019
Accepted: March 15, 2019
Article in press: March 16, 2019
Published online: April 27, 2019
Chronic rhinosinusitis (CRS) is a disease characterized by chronic inflammation of the mucous membrane lining the nose and paranasal sinuses. The immunological response of CRS is biased towards TH1 immunological response and its cytokine profile. On the other hand, allergic rhinitis (AR) is another form of chronic inflammation of the mucous membrane of the nose. It is broadly classified as seasonal (intermittent) or perennial (persistent). Here the immunological response is biased towards TH2 and its cytokine profile. However, both diseases; CRS and AR, may coexists especially in poorly controlled AR that is complicated by sinuses. Both diseases demonstrate leukocytes infiltration at the mucosal level. This entails a complex interaction between the ligand (chemokine or cytokine) and its specific receptor in the cell surface resulting into specific signal transduction and hence chemotaxis or infiltration of the inflamed tissue by inflammatory leukocytes.
CX3CR1 is the receptor for its ligand CX3CL1 or fractalkine and also for eotaxin 3[1,2] that is involved in adhesion and migration of leukocytes. CX3CR1 is expressed by lymphocytes, natural killer (NK) cells and monocytes. It is recently shown to be also expressed by human neutrophils in CRS and CRS associated with airways allergy. This further highlights the importance of this receptor in recruiting important types of inflammatory cells to the inflamed nose in CRS and/or AR. In the lower airway, CX3CR1 receptor signaling promotes TH2 survival in the inflamed lungs and promotes asthma inflammation.
CX3CR1 seems to be significantly upgraded in allergy of the airways. It was shown that allergen challenge upregulates the function of CX3CR1 in peripheral blood NK cells in AR patients and that NK cell infiltrated the epithelial layers of nasal tissue only in patients with CRS with allergy. Likewise, infiltrating neutrophils to the sub-epithelial layer of nasal mucosa showed maximum expression of CX3CR1 in CRS patients with combined airway allergy; AR and asthma. Interestingly, CX3CL1 or fractalkine was also shown to be expressed by inflammatory cells infiltrating the inflamed nasal tissue in CRS with AR. A maximum expression of fractalkine was seen in CRS patients with combined airway allergy; AR and asthma.
Although there are only few reports in the literature reporting on this novel receptor role in the nasal inflammation, it is clear from the existing evidences that CX3CL1/CX3CR1 axis in CRS and AR, play a pivotal role in promoting the chronicity of inflammation in CRS and AR patients, through inflammatory cells recruitment. It is interesting the predominance towards TH2 immunological response for the NK cells and neutrophils in this scenario. This makes this receptor a novel target for CRS with associated combined airways allergy. Therefore, it is mandatory to further explore the signaling of CX3CR1 in CRS and AR. Further studies are required to explore the role of this very important receptor in the pathophysiology of CRS and AR.
While Anti FKN (E6011; KANAb001) is under continuous evolution and evaluation as pharmacological target for CXCL1/CX3CR1 axis in rheumatoid arthritis patients, the author believes a similar approach in blocking CX3CR1 would be a promising therapeutic modality in treating inflammation seen in CRS and AR, especially the recalcitrant CRS and severe AR. Blocking of this receptor can attenuate the inflammatory cells influx in the epithelial and sub-epithelial layers of the nasal mucosa of NK cells and neutrophils, respectively.
Manuscript source: Invited manuscript
Specialty type: Otorhinolaryngology
Country of origin: Belgium
Peer-review report classification
Grade A (Excellent): 0
Grade B (Very good): B, B
Grade C (Good): 0
Grade D (Fair): 0
Grade E (Poor): 0
P-Reviewer: Ciuman RR, Coskun A S-Editor: Cui LJ L-Editor: A E-Editor: Zhang YL